Trabectedin is particularly active in heavily pretreated, BRCA mutated and/or BRCAness phenotype recurrent ovarian cancer patients. Toxicity profile appear in line with what reported in literature. Trabectedin may represent a valuable option in recurrent platinum sensitive ovarian cancer patients, not willing to receive or not able to receive further platinum-based treatments. In platinum resistant BRCA mutated and/or BRCAness phenotype patients the activity of the drug appears of particular interest and merits further evaluation.
from Cancer via ola Kala on Inoreader http://ift.tt/1Idxnsw
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου